Elanix Biotechnologies

We are a tissue regeneration company dedicated to using innovative cell technologies, advancing patient wound care and healing processes

Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, gynecological and dermatological conditions. The Company is headquartered in Berlin, Germany with offices in Nyon, Canton Vaud, Switzerland and Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.

JUNE BUSINESS UPDATE

A message from Tomas J. Svoboda, CEO

Ladies and Gentleman,

First of all, please let me thank you for your commitment and positive spirit. In the past few months, we have proved once again how fundamentally strong the Elanix team is and how determined we are despite all the difficulties encountered in our day-to-day work.

I would like to share an overview of our second quarter with you, as well as further details on where we have reached and progress we have made.

SCIENTIFIC RATIONALE

Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.

MARKETED PRODUCTS & PIPELINE

Elanix owns two advanced skin care products, GYNrepair® and SKINrepair®, marketed in Switzerland since 2012 for dermatological and gynecological applications.

Elanix is developing a bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts to accelerate regeneration and improve quality of skin following acute burns.

PARTNERS

BioReliance
EasyWell
goetzpartners
Sincopharm SA

NEWS